t
Haleon plc announced that Marie-Anne Aymerich, an Independent Non-Executive Director (PDMR), purchased Ordinary Shares in the Company. This transaction involved 21,300 Ordinary Shares at a price of £4.051 per share on 9 May 2025 on the London Stock Exchange.
| Date | 13 May 2025 |
| Time | 12:30:00 |
| Category | Director/PDMR dealings |
| ID | 4838I |
Annual Report and Accounts (to 2024-12-31)
Haleon plc: Director/PDMR Shareholding
13 May 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").
On 13 May 2025, the Company received notification of the following transaction as detailed below.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Marie-Anne Aymerich |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Independent Non-Executive Director - PDMR |
|||
|
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Haleon plc |
|||
|
b)
|
LEI
|
549300PSB3WWEODCUP19 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of £0.01 each
|
|||
|
|
|
||||
|
Identification code |
GB00BMX86B70
|
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares in the Company |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
£4.051 |
21,300 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
N/A - single transaction |
|||
|
|
|
||||
|
- Aggregated volume |
|
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
9 May 2025 |
|||
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON) |
|||
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.